KPRX · Kiora Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | - | $0 | $20.0K | $16.00M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.12M | - | $2.73M | $2.59M | $2.53M | - | $1.32M | $906.7K | $1.49M | - |
| SG&A | $1.61M | - | $1.44M | $1.35M | $1.49M | - | $1.38M | $1.54M | $1.30M | - |
| Total Operating Expenses | $2.51M | - | $794.4K | $2.40M | $2.33M | - | $3.60M | $2.56M | $2.78M | - |
| D&A | $10.6K | - | - | - | $318 | - | - | - | $4.9K | - |
| Operating Income | ($2.51M) | - | ($794.4K) | ($2.40M) | ($2.33M) | - | ($3.60M) | ($2.54M) | $13.22M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | ($643.1K) | ($112.1K) | $0 | - | - | - | - | - |
| Net Income | ($2.42M) | - | $26.8K | ($2.15M) | ($2.19M) | - | ($3.41M) | ($2.22M) | $13.45M | - |
| EPS - Basic | ($0.58) | - | $0.01 | ($0.54) | ($0.52) | - | ($0.81) | ($0.53) | $4.68 | - |
| EPS - Diluted | ($0.58) | - | $0.01 | ($0.54) | ($0.52) | - | ($0.81) | ($0.53) | $3.42 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.96M | $8.70M | $5.51M | $1.03M | $3.77M | $3.79M | $5.64M | $6.58M | $31.28M | $2.45M |
| Accounts Receivable | $1.54M | $1.52M | $1.21M | $2.42M | $1.34M | $601.2K | $1.78M | $1.34M | $0 | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $594.9K | $1.06M | $241.5K | $282.5K | $942.5K | $415.6K | $660.4K | $268.6K | $323.1K | $206.3K |
| Current Assets | $18.68M | $21.75M | $22.69M | $24.74M | $27.11M | $29.71M | $31.65M | $31.83M | $33.48M | $4.74M |
| Total Assets | $21.23M | $24.25M | $29.86M | $31.95M | $34.02M | $36.48M | $38.51M | $40.81M | $42.44M | $13.71M |
| Current Liabilities | $2.80M | $3.63M | $2.58M | $3.19M | $5.27M | $6.01M | $3.53M | $1.66M | $1.59M | $1.63M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $7.29M | $8.13M | $7.45M | $9.82M | $10.32M | $10.72M | $8.48M | $7.71M | $7.54M | $7.60M |
| Stockholders' Equity | $13.93M | $16.13M | $22.41M | $22.13M | $23.70M | $25.76M | $30.03M | $33.10M | $34.90M | $6.11M |
| Retained Earnings | ($156.64M) | ($154.22M) | ($147.70M) | ($147.73M) | ($145.58M) | ($143.38M) | ($139.16M) | ($135.75M) | ($133.52M) | ($146.98M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.16M) | - | - | - | ($2.70M) | - | - | - | $13.62M | - |
| Investing Cash Flow | $5.40M | - | - | - | $0 | - | - | - | - | - |
| Financing Cash Flow | ($842) | - | - | - | $0 | - | - | - | $15.25M | - |
| CapEx | $5.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($3.17M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | -12724.4% | 82.6% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | 82.7% | - |
| Net margin | - | - | - | - | - | - | - | -11108.2% | 84.1% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.31 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | 4533.4% | 9.3% | - |
| SG&A / Revenue | - | - | - | - | - | - | - | 7689.9% | 8.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -11.4% | - | 0.1% | -6.7% | -6.4% | - | -8.9% | -5.4% | 31.7% | - |
| Return on equity | -17.4% | - | 0.1% | -9.7% | -9.3% | - | -11.4% | -6.7% | 38.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.68 | 5.99 | 8.79 | 7.76 | 5.14 | 4.94 | 8.97 | 19.22 | 21.02 | 2.90 |
| Quick ratio | 6.68 | 5.99 | 8.79 | 7.76 | 5.14 | 4.94 | 8.97 | 19.22 | 21.02 | 2.90 |
| Cash ratio | 3.92 | 2.39 | 2.13 | 0.32 | 0.71 | 0.63 | 1.60 | 3.97 | 19.63 | 1.50 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.52 | 1.50 | 1.33 | 1.44 | 1.44 | 1.42 | 1.28 | 1.23 | 1.22 | 2.24 |
| Liabilities / Assets | 0.34 | 0.34 | 0.25 | 0.31 | 0.30 | 0.29 | 0.22 | 0.19 | 0.18 | 0.55 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.38 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | 24479d | 0d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 278.0x | - | - | - | - | - | 1.9x | - |
| P / B | 0.6x | - | 0.5x | 0.5x | 0.5x | - | 0.5x | 0.5x | 6.4x | - |
| P / S | - | - | - | - | - | - | - | 875.8x | 13.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | 14.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | -100.0% | -100.0% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | 42.9% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -7.7% | - | 77.9% | 5.8% | - | - | 39.1% | 3.3% | - | - |
| Net income growth (YoY) | -10.3% | - | - | 3.1% | - | - | 40.8% | 15.0% | - | - |
| EPS growth (YoY) | -11.5% | - | - | -1.9% | - | - | 9.0% | 32.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -41.2% | -37.4% | -25.4% | -33.2% | -32.1% | 321.6% | 270.6% | 142.6% | 243.7% | -46.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$16.02M totalReportable Segment$16.02M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing KIORA PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.